However, efforts have been made to increase CAR-T efficacy and safety by directing delivery locally to the surgical site and by targeting proteins overexpressed in HNSCC tumor tissue compared to local adjacent tissue, namely FAP, HER3, and NKGD2. This evidence concerns the gene ERBB3 and neoplasm.